NAFLD comprises a pathological spectrum characterized ... In NAFLD-related cirrhosis, liver histology may no longer show inflammation or even steatosis, and this likely represents the largest ...

The spectrum of ALD includes steatosis with or without fibrosis in virtually all individuals with an alcohol consumption of >80 g/day, alcoholic steatohepatitis of variable severity in 10–35% and ...

NAFLD spectrum of disease involves progression from steatosis (NAFL), to steatohepatitis (NASH), cirrhosis and hepatocellular carcinoma (HCC). Despite clinical and public health significance, current ...

Objective Population-based data are lacking regarding the risk of overall and cause-specific mortality across the complete histological spectrum ... simple steatosis, non-fibrotic steatohepatitis ...

NAFLD encompasses several liver diseases, ranging from simple steatosis to more severe inflammatory and fibrotic forms. Ultimately, this can lead to liver cirrhosis and hepatocellular ... In ...

About 20% of people with MASH can progress to late-stage liver scarring which is called cirrhosis. Approximately three million people in the United States are estimated to have MASH-related cirrhosis.

A study shows that patients with obesity and fatty liver-related cirrhosis who had bariatric (weight-loss) surgery significantly lowered their future risk of developing serious liver complications ...

Background: Biopsy is the usual gold standard for liver steatosis assessment. The aim of this study was to identify a panel of biomarkers (SteatoTest), with sufficient predictive values ...

However, where it fell short was with respect to the failure at week 36 with the phase 2b SYMMETRY study, which used EFX to treat compensated cirrhosis patients due to MASH stage F4 fibrosis.

Assessment of liver fibrosis and cirrhosis is crucial for the management of patients with chronic hepatitis B. The presence of at least moderate liver fibrosis is an important indication for antiviral ...